Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
Authors:
- 20 August 2018
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 67 (11) , 1673-1683
Abstract
The recent development of immune checkpoint inhibitors for many types of cancers has prompted us to identify markers that predict patients with clinical benefits. Several trials on nivolumab for the treatment of esophageal squamous cell carcinoma (ESCC) have been performed worldwide, and the identification of markers specific to ESCC is urgently needed. We conducted a clinical trial on nivolumab for advanced ESCC (JapicCTI-No.142422) and investigated markers using peripheral blood collected from 20 patients enrolled in our institute, including 1 with a complete response (CR), 5 with a partial response (PR), 6 with a stable disease (SD), and 8 with a progressive disease (PD) as clinical responses. The expression of surface molecules and cytokine production by T cells were analyzed using flow cytometry, and clinicopathological factors and general blood parameters were examined. Albumin, neutrophils, %Tim3, %OX40, %CD103, %CD45RA−CD27−, and IL-1b after the first cycle of nivolumab treatment, but not at baseline, distinguished CR/PR from SD/PD patients. When markers to distinguish longer survivors with nivolumab therapy were analyzed, changes in these levels between baseline and after the first cycle of nivolumab treatment, but not levels at each period, were indicative, similar to the tumor burden. Among them, elevations in %Tim-3+CD4 had a marked impact on survival rates. In conclusion, dynamic elevations in %Tim-3 in T cells in the early period of nivolumab therapy have potential as a marker for the clinical responses and prognosis of advanced ESCC patients.Keywords
Funding Information
- the Project for Development of Innovative Research on Cancer Therapeutics
- Japan Agency for Medical Research and Development (15ck0106159h)
This publication has 26 references indexed in Scilit:
- ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pyloriInternational Journal of Cancer, 2016
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanomaJournal of Clinical Investigation, 2016
- Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancerOncotarget, 2016
- Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancersNature Medicine, 2016
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNature Communications, 2016
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- Four Functionally Distinct Populations of Human Effector-Memory CD8+ T LymphocytesThe Journal of Immunology, 2007